Habedank Dirk, Ewert Ralf, Hetzer Roland, Anker Stefan D
Department of Cardiology, Division of Applied Cachexia Research, Charité Campus Virchow-Klinikum, Berlin, Germany.
Int J Cardiol. 2009 Mar 20;133(1):46-50. doi: 10.1016/j.ijcard.2007.11.077. Epub 2008 Jan 29.
Cachexia is one of the terminating syndromes in pulmonary disease, and cachectic patients have an increased mortality even after lung transplantation (LTx). Our study assessed weight changes in cachectic patients after LTx compared to normal weight LTx recipients, and investigated differences in gender, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and primary pulmonary hypertension (PPH).
We prospectively examined 46 patients before and serially 3, 6, 12 and 24 months after LTx (25 female, 21 male; median age at transplantation 46.9+/-13.9 years, n=17 COPD, n=8 CF, n=9 PPH, n=12 other origin). Patients were subgrouped as cachectic (BMI<or=21 kg/m2, n=21), and non-cachectic (BMI >21, n=25).
Body weight increase was restricted to underweight patients: at 3 months (+2.1% vs. pre-transplant weight, p=0.28), 6 (+6.2%), 12 (+8.8%), and 24 months (+11.4%, all p<or=0.02). Non-cachectic patients suffered from weight loss at 3 months (-4.4%; p=0.02), and had non-significant weight gain at 6,12 and 24 months (+2.8 to 5.4%, all p>0.05). BMI pre LTx was correlated to weight gain after LTx (r=0.29 to 0.35; all p<0.05). Weight gain was not related to diagnosis (COPD, CF or PPH), gender or age.
Weight gain after LTx is highest in underweight recipients and a continuous process from 3 months to 2 years after LTx. The weight gain is independent from the primary lung disease, and healing of this disease by LTx can make cachexia reversible. Weight increase after LTx is not affected by gender, immunosuppressive regimen, renal function before LTx, or age.
恶病质是肺部疾病的终末期综合征之一,即使在肺移植(LTx)后,恶病质患者的死亡率仍会升高。我们的研究评估了LTx后恶病质患者与正常体重LTx受者的体重变化,并调查了性别、慢性阻塞性肺疾病(COPD)、囊性纤维化(CF)和原发性肺动脉高压(PPH)方面的差异。
我们前瞻性地检查了46例患者LTx前以及LTx后3、6、12和24个月时的情况(25例女性,21例男性;移植时的中位年龄为46.9±13.9岁,n = 17例COPD,n = 8例CF,n = 9例PPH,n = 12例其他病因)。患者被分为恶病质组(BMI≤21 kg/m²,n = 21)和非恶病质组(BMI>21,n = 25)。
体重增加仅限于体重过轻的患者:3个月时(较移植前体重增加2.1%,p = 0.28),6个月时(增加6.2%),12个月时(增加8.8%),以及24个月时(增加11.4%,所有p≤0.02)。非恶病质患者在3个月时体重减轻(-4.4%;p = 0.02),在6、12和24个月时体重有不显著的增加(增加2.8%至5.4%,所有p>0.05)。LTx前的BMI与LTx后的体重增加相关(r = 0.29至0.35;所有p<0.05)。体重增加与诊断(COPD、CF或PPH)、性别或年龄无关。
LTx后体重增加在体重过轻的受者中最高,并且是LTx后3个月至2年的一个持续过程。体重增加与原发性肺部疾病无关,通过LTx治愈该疾病可使恶病质可逆。LTx后的体重增加不受性别、免疫抑制方案、LTx前的肾功能或年龄的影响。